Slide 1: Fourth Quarter 2022 Earnings Presentation
ANGIODYNAMICS Fourth Quarter 2022 Earnings Presentation July 12, 2022 1
Slide 2: Forward-Looking Statement
Forward-Looking Statement Notice Regarding Forward-LookingStatements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, ca
Slide 3: Corporate Developments – Q4 and Full-Year Highlights
Corporate Developments – Q4 and Full-Year Highlights • Continued focused investment in our 3 key Med Tech platforms: Auryon, Thrombectomy & NanoKnife • Company Q4 revenue growth of 13.2% Ø Med Tech up 40.0%; Med Device up 6.1% Ø $9.6 million in Auryon sales Ø 10.0% YOY growth in Mechanical Thrombect
Slide 4: FY23 Guidance
FY23 Guidance FY23 Guidance Revenue $342 - $348 million Gross Margin 52.5% - 54.5% Med Tech 65% - 68% Med Device 45% - 48% Adjusted EPS $0.01 - $0.06 4
Slide 5: Fourth Quarter and Full-Year Highlights
Fourth Quarter and Full-Year Highlights Financial Performance $ in thousands (except per share data) Q4 FY2022 Q4 FY2021 Change FY2022 FY2021 Change Revenue $86,998 $76,842 13.2% $316,219 $291,010 8.7% Gross Margin 53.4% 55.1% (170 bps) 52.4% 53.9% (150 bps) Net Loss ($6,266) ($19,468) $13,202 ($26,
Slide 6: Fourth Quarter and Full-Year Highlights
Fourth Quarter and Full-Year Highlights Q4 Revenue Contribution Full-Year Revenue Contribution Med Tech Med Tech Q4 FY21 Med Device Q4 FY22 FY21 Med $10.5Device FY22 $17.6 21% 19% 25% 26% $59.7 79% 74% 75% 81% Q4 Revenue Growth Full-Year Revenue Growth Q4 FY21 Q4 FY22 FY21 FY22 19.6 22.6 78.7 41.2%
Slide 7: Sales Growth Over Prior Periods
Sales Growth Over Prior Periods Med Tech Q4 FY2022 FY2022 Endovascular Therapies Q4 FY2022 FY2022 Auryon* 110% 162% Auryon 110% 162% Thrombectomy** 11% 12% Mechanical Thrombectomy* 10% 16% NanoKnife® Disposables 16% 17% Thrombolytics 21% (6%) NanoKnife® Capital 0% (10%) Core Peripheral 3% 6% Venous
Slide 8: Fourth Quarter and Full-Year 2022 Results (unaudited)
Fourth Quarter and Full-Year 2022 Results (unaudited) $ in thousands (except per share data) Q4 FY2022 Q4 FY2021 Change FY2022 FY2021 Change Revenue $86,998 $76,842 13.2% $316,219 $291,010 8.7% Med Tech $22,611 $16,150 40.0% $78,717 $55,731 41.2% Med Device $64,387 $60,692 6.1% $237,502 $235,279 0.9
Slide 9: Fourth Quarter and Full-Year 2022 Gross Margin Walk
Fourth Quarter and Full-Year 2022 Gross Margin Walk Fourth Quarter Full-Year * Start-up costs include installation costs related to the Auryon lasers and costs related to transitioning 9 the manufacturing of AlphaVac to AngioDynamics.
Slide 10: Full-Year 2022 Cash Walk
Full-Year 2022 Cash Walk (11.9) 10 >) angiodynamics
Slide 11: Focused Transformation
FOCUSED TRANSFORMATION FY2025 Planned Thrombectomy & PE portfolio U.S. Total Addressable Markets FY2023 additions & new indications increase market access Planned Thrombectomy & NanoKnife System portfolio additions & new indications FY2021 increase market access $8.0B Launch of the Auryon System giv
Slide 12: Med Tech Platform – Expansion Opportunities
Med Tech Platform – Expansion Opportunities Developing our Med Tech platforms potentially expands our TAMs Arterial Thrombectomy Atherectomy Coronary Med Device Atherectomy** Prostate* Left Atrium FY2023 TAM Portfolio Future TAM Chronic DVT** $6B Expansion >$10B DVT European MedTech Pulmonary Emboli
Slide 13: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 13
Slide 14: Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS
Reconciliation of GAAP to Non-GAAP Reconciliation of Net Loss to Adjusted Net Income (Loss) and EPS EBITDA (in thousands) (in thousands, except per share data) (1) Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-of